Alirocumab cuts cardiac mortality in patients with diabetes

Findings provide 'greater reassurance' of glycaemic safety of PCSK9 inhibitors, study authors say

The PCSK9 inhibitor alirocumab conveys almost double the cardio-protective benefit in patients with diabetes following acute coronary syndrome than those without diabetes, a large international trial has shown.